Back to Search
Start Over
The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: A cohort study
- Source :
- Paediatrics Publications, Orphanet Journal of Rare Diseases
- Publication Year :
- 2016
- Publisher :
- Scholarship@Western, 2016.
-
Abstract
- Background - There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants. Methods - The cohort included all children who received newborn screening in Ontario between April 1, 2006 and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations, to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were used to compare those with false positive results for MCADD to those with negative newborn screening results, stratified by age at service use. Results - We identified 43 infants with a false positive newborn screening result for MCADD during the study period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations (IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health services use were not observed after the first year of life. Conclusions - The higher use of some health services among false positive infants during the first year of life may be explained by a psychosocial impact of false positive results on parental perceptions of infant health, and/or by differences in underlying health status. Understanding the impact of false positive newborn screening results can help to inform newborn screening programs in designing support and education for families. This is particularly important as additional disorders are added to expanded screening panels, yielding important clinical benefits for affected children but also a higher frequency of false positive findings. This study was Funded through a Canadian Institutes of Health Research (CIHR) Emerging Team Grant (TR3-119195). Maria Karaceper received a graduate scholarship through a charitable donation to the Children’s Hospital of Eastern Ontario. This study was performed at the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).
- Subjects :
- 0301 basic medicine
Male
medicine.medical_specialty
education
Pharmacology toxicology
Acyl-CoA dehydrogenase deficiency
Acyl-CoA Dehydrogenase
Lipid Metabolism, Inborn Errors
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Neonatal Screening
030225 pediatrics
Medicine
Humans
Genetics(clinical)
Pharmacology (medical)
Health services utilization
Child
health care economics and organizations
Genetics (clinical)
Medicine(all)
Ontario
Newborn screening
business.industry
Research
Infant, Newborn
nutritional and metabolic diseases
Metabolic diseases
General Medicine
Health Care Costs
Medium-Chain Acyl-CoA Dehydrogenase Deficiency
3. Good health
Hospitalization
030104 developmental biology
System impact
Donation
Family medicine
Child, Preschool
Christian ministry
Female
business
Neonatal screening
Cohort study
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Paediatrics Publications, Orphanet Journal of Rare Diseases
- Accession number :
- edsair.doi.dedup.....a7ad061c276ba812a0dc2da493de3965